Prevalence and specificity of red-blood-cell antibodies in a multiethnic South and East Asian patient population and influence of using novel MUT+Mur+ kodecytes on its detection
Article first published online: 19 MAY 2011
© 2011 The Author(s). Vox Sanguinis © 2011 International Society of Blood Transfusion
Volume 102, Issue 1, pages 65–71, January 2012
How to Cite
Nadarajan, V. S., Laing, A. A., Saad, S. M. and Usin, M. (2012), Prevalence and specificity of red-blood-cell antibodies in a multiethnic South and East Asian patient population and influence of using novel MUT+Mur+ kodecytes on its detection. Vox Sanguinis, 102: 65–71. doi: 10.1111/j.1423-0410.2011.01507.x
- Issue published online: 26 DEC 2011
- Article first published online: 19 MAY 2011
- Received: 20 February 2011, revised 14 April 2011, accepted 18 April 2011, published online 19 May 2011
- blood groups;
- RBC antigens and antibodies;
- South-East Asia;
Background and Objectives Appropriate screening for irregular red-cell antibodies is essential for ensuring transfusion compatibility and for antenatal management of mothers at risk of haemolytic disease of the foetus and newborn. Screening for all relevant antibodies is, however, limited by screening cells that do not express antigens present in the patient and donor population. Technology to artificially incorporate antigens into red cells is currently available and may be an option for customizing screening cells.
Materials and Methods We sought to identify retrospectively the changing patterns of alloantibody prevalence in our multiethnic population on change of screening cells. Antibody screening records of 143 501 patients tested from 2004 to 2010 were retrieved and divided into two groups: period-1 (2004–2008) and period-2 (2009–2010). During period-1, standard screening cells were used while in period-2, MUT+Mur+ KODE™ transformed red cells (kodecytes) were used.
Results Four per cent of samples tested during period-2 were positive on antibody screening compared to 3·2% in period-1. Specific antibodies, excluding anti-D, were identified in 1·66% and 1·52% of patients in period-2 and -1, respectively. When confined to antibodies of clinical significance only, period-2 showed higher alloantibody prevalence of 1·16% as compared to 0·66% in period-1. Antibodies to glycophorin variants of MNS (vMNS) were more commonly detected while antibodies to Lewis antigens declined during period-2.
Conclusion Antibodies to vMNS antigens are common in South and East Asian populations and are often missed when using standard screening cells. Use of specifically engineered screening cells to express red-cell antigens artificially is beneficial in detecting the diverse alloantibodies present in our population.